Authors’ reply to Marjoribanks and colleagues, Rossouw and colleagues, Schroll and Lundh, and McPhersonBMJ 2012; 345 doi: https://doi.org/10.1136/bmj.e8164 (Published 03 December 2012) Cite this as: BMJ 2012;345:e8164
- Louise Lind Schierbeck, registrar1,
- Lars Køber, professor, consultant2,
- Jens-Erik Beck Jensen, associate professor, consultant1
- 1Department of Endocrinology, Hvidovre Hospital, 2650 Hvidovre, Denmark
- 2Department of Cardiology, Rigshospitalet, Copenhagen, Denmark
We are grateful for all of the interest in our paper1; more extensive answers are available at bmj.com (www.bmj.com/content/345/bmj.e6409/rr/612351).
Although randomisation is an important part of any trial, we acknowledge that performance and detection bias exist in open label trials,2 3 but these biases are less important when endpoints are driven by mortality. Furthermore, no trial of hormone replacement therapy (HRT)—including the Women’s Health Initiative—conducted in women with a uterus is completely blinded.4 5 …